NASDAQ:STOK | Free Cash Flow | Stoke Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$60.58M$353,000.00-$60.94M
2025-12-31-$30.45M$232,000.00-$30.69M
2025-03-31$131.83M$152,000.00$131.68M116.65%
2024-12-31-$23.19M$42,000.00-$23.24M
2024-03-31-$24.57M$12,000.00-$24.58M
2023-12-31-$20.65M$229,000.00-$20.88M
2023-03-31-$21.36M$165,000.00-$21.52M
2022-12-31-$22.37M$409,000.00-$22.78M
2022-03-31$32.49M$841,000.00$31.65M
2021-12-31-$16.26M$203,000.00-$16.46M
2021-03-31-$20.14M$204,000.00-$20.34M
2020-12-31-$10.93M$90,000.00-$11.02M
2020-03-31-$10.77M$610,000.00-$11.38M
2019-12-31-$10.2M$568,000.00-$10.77M
2019-03-31-$6.53M$92,000.00-$6.62M
2018-12-31-$3.52M$93,000.00-$3.61M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$45.59M$670,000.00$44.92M
2024-12-31-$86.85M$203,000.00-$87.05M
2023-12-31-$81.07M$1.62M-$82.68M
2022-12-31-$31.87M$3.96M-$35.83M
2021-12-31-$66.91M$1.2M-$68.11M
2020-12-31-$42.22M$1.05M-$43.27M
2019-12-31-$31.06M$1.64M-$32.69M
2018-12-31-$10.96M$935,000.00-$11.9M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.